

# Transthyretin amyloid cardiomyopathy – challenges in diagnostic and therapeutic protocol

Nejra Mlačo-Vražalić<sup>1,\*</sup>,  
Ada Dozić<sup>1</sup>,  
Nejra Prohić<sup>1</sup>,  
Mirza Skalonja<sup>1</sup>,  
Šejla Bišćević<sup>1</sup>,  
Jasmin Idrizović<sup>1</sup>,  
Edin Begić<sup>1,2</sup>

<sup>1</sup>General Hospital "Prim. Dr. Abdulah Nakaš", Sarajevo, Bosnia and Herzegovina

<sup>2</sup>School of Medicine, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina

**KEYWORDS:** amyloidosis, cardiomyopathies, diagnosis.


**CITATION:** *Cardiol Croat.* 2024;19(11-12):430. | <https://doi.org/10.15836/ccar2024.430>

**\*ADDRESS FOR CORRESPONDENCE:** Nejra Mlačo-Vražalić. General Hospital "Prim.dr Abdulah Nakaš", Kranjčevićeva 12, 71000 Sarajevo, Bosnia and Herzegovina. / Phone: +387 33 285 100 / E-mail: [nejra.ml@gmail.com](mailto:nejra.ml@gmail.com)

**ORCID:** Nejra Mlačo-Vražalić, <https://orcid.org/0000-0002-3299-6899> • Ada Dozić, <https://orcid.org/0000-0002-2664-810X> • Nejra Prohić, <https://orcid.org/0000-0001-6789-1096> • Mirza Skalonja, <https://orcid.org/0009-0008-2211-9949> • Šejla Bišćević, <https://orcid.org/0000-0002-7516-8698> • Jasmin Idrizović, <https://orcid.org/0009-0006-3598-3870> • Edin Begić, <https://orcid.org/0000-0001-6842-262X>

**Goal:** To present protocol for diagnosis and differentiation of cardiac amyloidosis, and to review treatment options for patients with transthyretin amyloid cardiomyopathy (ATTR-CM) in daily clinical practice.

**Case presentation:** 70-year-old man was hospitalized with symptoms consistent with peripheral neuropathy, polyarthralgia, Raynaud syndrome and dyspnea on exertion. His past medical history included hypertension and hypothyroidism. Electrocardiogram (ECG) revealed left axis deviation, low voltage and intermittent atrial fibrillation. Echocardiography showed concentric left ventricular hypertrophy with granular speckling, normal ejection fraction and grade 1 diastolic dysfunction. Moderate aortic stenosis with mild aortic regurgitation was present, as well as moderate mitral regurgitation and mild tricuspid regurgitation. Subsequent analysis of global longitudinal strain (GLS) showed GLS reduction with nonspecific apical sparing pattern (Figure 1). Infiltrative cardiomyopathy was suspected, and we obtained serum and urine protein electrophoresis with immunofixation and the kappa/lambda ratio, which were negative for clonal plasma cell dyscrasia. Bone scintigraphy showed Technetium 99m-methyl diphosphonate uptake in the myocardium which was less/similar to ribs uptake (Perugini grade 1-2). Cardiac magnetic resonance (CMR) was obtained since scintigraphy results were inconclusive, and it confirmed cardiac amyloidosis pattern. Patient had significantly high levels of rheumatoid factor, without specific diagnostic criteria for rheumatological diseases. Electromyoneurography of arms and legs confirmed severe polyneuropathy. Since the patient presented with both cardiomyopathy and neuropathy, disease-specific therapies to consider would be tafamidis and patisiran. Genetic testing should be performed to detect specific mutations and to guide the treatment.



**FIGURE 1.** Analysis of global longitudinal strain (GLS) showed GLS reduction (-7.1%) without typical pattern. Perugini grade 2 with a region of interest (ROI) ratio of 1.51.

**RECEIVED:**  
October 6, 2024

**ACCEPTED:**  
October 31, 2024



several 'red flags' for ATTR-CM, should guide clinicians to perform echocardiography. After establishing the diagnosis, patient should be treated with specific treatment based on the dominant disease phenotype.<sup>1-3</sup>

## LITERATURE

1. Cotella J, Randazzo M, Maurer MS, Helmke S, Scherrer-Crosbie M, Soltani M, et al. Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic study. *Eur Heart J Cardiovasc Imaging.* 2024 May 31;25(6):754-761. <https://doi.org/10.1093/ehjci/jeae021>
2. Kessler L, Fragoso Costa P, Kersting D, Jentzen W, Weber M, Lüdtke P, et al. Quantitative 99mTc-DPD-SPECT/CT assessment of cardiac amyloidosis. *J Nucl Cardiol.* 2023 Feb;30(1):101-111. <https://doi.org/10.1007/s12350-022-02960-3>
3. Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. *Eur Heart J.* 2021 Apr 21;42(16):1554-1568. <https://doi.org/10.1093/eurheartj/ehab072>